A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsored by Stemline Therapeutics, Inc.
About this study
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Where this study is enrolling (4)
- I'm interested
Winship Cancer Institute, Emory University
Atlanta, Georgia
- I'm interested
University of Chicago Medical Center
Chicago, Illinois
- I'm interested
University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)
Chicago, Illinois
- Call 877-632-6789
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Participant has advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.
- ✓Presence of genetic alterations in PIK3CA/AKT1/PTEN in participants' tumor tissue.
- ✓Participant must have received at least 1 prior line of endocrine therapy for advanced/metastatic disease or participant who has radiological evidence of breast cancer recurrence or progression during or within 12 months from the end of adjuvant treatment with endocrine therapy, as these participants are considered as first-line relapsed participants.
- ✓Progression on previous cyclin-dependent kinase 4 and 6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.
Exclusion criteria
- ✕Active or newly diagnosed central nervous system metastases.
- ✕Participants with advanced, symptomatic visceral spread, who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \>50%.
- ✕Participants with any toxicities related to prior radiation therapy that have not resolved to baseline or to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 Grade ≤1, except alopecia and peripheral sensory neuropathy (Grade ≤2).
- ✕Note: Other inclusion/exclusion criteria may apply.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.